Abstract
Purpose: To study the influence of sitagliptin on blood glucose, lipid and pancreatic β cell function in type II diabetes mellitus (T2DM) patients.Methods: Two groups of T2DM patients (100/group) received either metformin only (control group), or metformin plus sitaglipin (study group) for 3 months. Blood lipid profiles, fasting blood glucose (FBG), indices of pancreatic function and insulin resistance were assayed using standard biochemical methods.Results: The metformin-sitaglipin combination resulted in significant decreases in FBG, 2-h PBG, HbAlc total cholesterol (TC), triacylglycerol, and low-density lipoprotein cholesterol (LDL-C), when compared with the metformin-only treatment (p < 0.05). Although there were significant decreases in pancreatic secretion of insulin, fasting insulin, and 2 h postprandial insulin in the two groups, these parameters were significantly lower in the metformin-only treated patients than in those with combination treatment (p < 0.05).Conclusion: Sitagliptin normalizes fasting blood glucose, lipid profiles and insulin secretion in type II diabetes mellitus (T2DM) patients.Keywords: Type 2 diabetes mellitus, Sitagliptin, Blood glucose, Pancreatic islet function, Insulin
Highlights
Diabetes mellitus (DM) affects millions of people globally, with T2DM accounting for most of the reported cases of diabetes worldwide
There are Sitagliptin inhibits the activity of dipeptidyl peptidase-4 (DDP-4) which controls the metabolism of hypoglycin-like peptide-1 (GLP-1) in diabetic patients
The combination treatment with metformin and sitagliptin led to significant increases in FINS, 2-h PINS and HOMA-β, when compared with patients treated with metformin alone, but HOMA-IR was significantly higher in the control group (p < 0.05)
Summary
Diabetes mellitus (DM) affects millions of people globally, with T2DM accounting for most of the reported cases of diabetes worldwide. It is known that T2DM is a primary DM caused by a combination of different factors such as insulin secretion deficiency and insulin resistance [1,2] This disease is characterized by impaired function or failure of the pancreatic β cells, and disorders in lipid and carbohydrate metabolism, often accompanied by abnormal increases in the levels of blood glucose and lipids. Sitagliptin inhibits the activity of dipeptidyl peptidase-4 (DDP-4) which controls the metabolism of hypoglycin-like peptide-1 (GLP-1) in diabetic patients. It has attracted huge attention as a new oral hypoglycemic drug [5]. The present study was carried out to assess the clinical effect of sitagliptin on blood glucose, lipids and pancreatic β cell function in T2DM subjects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
